SSRI's and Suicidality

SSRI 与自杀

• 批准号: 8020771
• 负责人: GREGORY G SIMON
• 金额: $ 58.64万
• 依托单位: KAISER FOUNDATION HEALTH PLAN OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-24 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8020771
• 关键词: Accident and Emergency department; Adolescent; Adult; Affect; Age; Antidepressive Agents; Area; Boxing; Child; Data; Diagnosis; Experimental Designs; Feeling suicidal; Future; Geographic Locations; Goals; Health Planning; Hospitalization; Incidence; Label; Left; Longitudinal Studies; Major Depressive Disorder; Mental Depression; Mental Health; Mental disorders; Methods; Moods; Outcome; Outcome Measure; Policies; Public Health; Reporting; Research; Research Design; Research Personnel; Resources; Risk; Risk Factors; Sampling; Selective Serotonin Reuptake Inhibitor; Series; Simulate; Suicide; Suicide attempt; Surveillance Methods; Surveillance Program; The Sun; Therapeutic; Time; Time Series Analysis; United States Agency for Healthcare Research and Quality; Violence; Visit; Youth; accomplished suicide; adverse outcome; aged; experience; improved; interest; medical attention; primary outcome; programs; secondary outcome; sex; suicidal behavior; trend; young adult

Introduction and Overview Our objective in this study is to evaluate the possible unintended consequences ofthe FDA decision to issue a warning regarding the prescribing of SSRIs to children and adolescents and require a BBW on antidepressant labels. Depression is prevalent among youth in the US and is a risk factor for suicide.(21) Thus, it is of critical importance that the public health implications of possible decreases in antidepressant treatment rates be fully understood. While much research has been conducted in this area, suboptimal study design, absence of long-term trend data, and/or lack of statistical power have left important questions about the effects ofthe warnings on suicidality unanswered. Below we review the important studies to date and highlight how our proposed research will fill gaps in our understanding ofthe relationships among FDA warnings (and associated media reports), antidepressant treatment in youth, and risk of suicidal behavior.

介绍和概述 本研究的目的是评估FDA决定对儿童和青少年处方SSRIs发出警告并要求抗抑郁药标签上注明BBW的可能意外后果。抑郁症在美国青年中很普遍，是自杀的危险因素。(21)因此，充分了解抗抑郁药治疗率可能下降的公共卫生影响至关重要。虽然在这一领域进行了大量研究，但次优的研究设计， 长期趋势数据的缺乏和/或统计效力的缺乏使得关于警告对自杀倾向的影响的重要问题没有得到解答。下面，我们回顾了迄今为止的重要研究，并强调我们提出的研究将如何填补我们对FDA警告（和相关媒体报道），青年抗抑郁治疗和自杀行为风险之间关系的理解空白。